About Grifols
Grifols is a company based in Barcelona (Spain) founded in 1909. The company has 23,830 employees as of December 31, 2024. Grifols has completed 8 acquisitions, including Alkahest, Araclon and Biotest. Grifols operates in a competitive market with competitors including Biogen, UCB, Kymeratx, PureTech Health and Generate Biomedicines, among others.
- Headquarter Barcelona, Spain
- Employees 23830 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Grifols, S.A. Class A
-
Annual Revenue
$7.49 B (USD)9.41as on Dec 31, 2024
-
Net Profit
$163.02 M (USD)270.81as on Dec 31, 2024
-
EBITDA
$1.62 B (USD)37.41as on Dec 31, 2024
-
Latest Funding Round
$21 M (USD), Grant
Jan 15, 2025
- Investors
-
Employee Count
23830
as on Dec 31, 2024
-
Investments & Acquisitions
Alkahest
& 7 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Grifols
Grifols is a publicly listed company on the BME with ticker symbol GRF in Spain, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Grifols
Unlock access to complete
Unlock access to complete
Sales and Marketing
56 people
Leadership Team
54 people
Software Development Team
22 people
Senior Team
13 people
Product Management Team
12 people
Medical Team
10 people
Data Analysis and Operations Team
7 people
Operations Team
5 people
Unlock access to complete
Funding Insights of Grifols
Investors in Grifols
Grifols has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include The Michael J. Fox Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research for Parkinson's disease is funded by the foundation.
|
Locked | Locked | Locked |
Investor details for Grifols
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Grifols
Grifols has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Alkahest, Araclon and Biotest.
Investment portfolio details for Grifols
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies derived from blood to treat neurological diseases.
|
Locked | Locked | 2014 | Locked | |
|
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
Locked | Locked | 2011 | Locked | |
|
Robotic automation for compounding intravenous treatments is provided.
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for Grifols
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Grifols
Detailed financials for Grifols
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Grifols Comparisons
Peer comparison for Grifols
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Grifols
Grifols operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Kymeratx, PureTech Health and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Grifols
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Grifols
Complete news archive for Grifols
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Grifols
Grifols was founded in 1909 and raised its 1st funding round 116 years after it was founded.
Grifols is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Raimon Grifols Roura is the current CEO of Grifols.
As of Dec 31, 2024, the latest employee count at Grifols is 23,830.
Annual revenue of Grifols is $7.49B as on Dec 31, 2024.
Grifols was founded in 1909 in Barcelona, Spain, and operates in the biopharmaceutical sector. Plasma-derived medicines and transfusion medicines are produced for therapeutic areas including neurology, immunology, hepatology, intensive care, pulmonology, hematology, and infectious diseases. Operations focus on treating a broad range of conditions through these specialized therapies, with global reach from its European base.
Grifols's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
Yes, Grifols is publicly traded on BME under the ticker symbol GRF.
Grifols has 1 investor. Key investors include The Michael J. Fox Foundation.
The ticker symbol of Grifols is GRF on BME.